Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population
- PMID: 33426547
- PMCID: PMC8323818
- DOI: 10.1039/d0an01769h
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population
Abstract
Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.
Conflict of interest statement
There are no conflicts of interest to declare.
Figures



Similar articles
-
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.Theranostics. 2020 Feb 10;10(7):3151-3163. doi: 10.7150/thno.41362. eCollection 2020. Theranostics. 2020. PMID: 32194860 Free PMC article.
-
BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.Biochem Biophys Res Commun. 2017 Sep 30;491(4):939-945. doi: 10.1016/j.bbrc.2017.07.139. Epub 2017 Jul 26. Biochem Biophys Res Commun. 2017. Retraction in: Biochem Biophys Res Commun. 2018 Mar 18;497(4):1184. doi: 10.1016/j.bbrc.2018.03.006. PMID: 28756223 Retracted.
-
Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Oncotarget. 2016 Feb 23;7(8):9163-74. doi: 10.18632/oncotarget.7036. Oncotarget. 2016. PMID: 26824321 Free PMC article.
-
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2. Mol Cancer. 2015. PMID: 26654227 Free PMC article. Review.
-
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.Anticancer Agents Med Chem. 2019;19(17):2047-2059. doi: 10.2174/1871520619666190925143216. Anticancer Agents Med Chem. 2019. PMID: 32009599 Review.
Cited by
-
Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.Cancers (Basel). 2021 Apr 30;13(9):2167. doi: 10.3390/cancers13092167. Cancers (Basel). 2021. PMID: 33946435 Free PMC article. Review.
-
Drug screening at single-organoid resolution via bioprinting and interferometry.Nat Commun. 2023 Jun 6;14(1):3168. doi: 10.1038/s41467-023-38832-8. Nat Commun. 2023. PMID: 37280220 Free PMC article.
-
Quantitative Phase Imaging: Recent Advances and Expanding Potential in Biomedicine.ACS Nano. 2022 Aug 23;16(8):11516-11544. doi: 10.1021/acsnano.1c11507. Epub 2022 Aug 2. ACS Nano. 2022. PMID: 35916417 Free PMC article. Review.
-
Quantitative phase imaging for characterization of single cell growth dynamics.Lasers Med Sci. 2023 Oct 18;38(1):241. doi: 10.1007/s10103-023-03902-2. Lasers Med Sci. 2023. PMID: 37851109 Review.
References
-
- Hata A. N. Niederst M. J. Archibald H. L. Gomez-Caraballo M. Siddiqui F. M. Mulvey H. E. Maruvka Y. E. Ji F. Bhang H.-E. C. Krishnamurthy Radhakrishna V. Siravegna G. Hu H. Raoof S. Lockerman E. Kalsy A. Lee D. Keating C. L. Ruddy D. A. Damon L. J. Crystal A. S. Costa C. Piotrowska Z. Bardelli A. Iafrate A. J. Sadreyev R. I. Stegmeier F. Getz G. Sequist L. V. Faber A. C. Engelman J. A. Nat. Med. 2016;22:262–269. doi: 10.1038/nm.4040. - DOI - PMC - PubMed
-
- Song K.-A. Hosono Y. Turner C. Jacob S. Lochmann T. L. Murakami Y. Patel N. U. Ham J. Hu B. Powell K. M. Coon C. M. Windle B. E. Oya Y. Koblinski J. E. Harada H. Leverson J. D. Souers A. J. Hata A. N. Boikos S. Yatabe Y. Ebi H. Faber A. C. Clin. Cancer Res. 2018;24:5658. doi: 10.1158/1078-0432.CCR-18-0304. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources